DESTINY-Breast05 Findings -

Name: DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Uploaded: 2026-06-03T04:00:00+00:00
Duration: 3 min 31 s
Description: Trastuzumab deruxtecan (T-DXd) is a well-established treatment approach for metastatic breast cancer. The open-label, multicenter, phase 3 DESTINY-Breast05

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Oncology and Hematology
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Sara A. Hurvitz, MD, FACP
- Sara A. Hurvitz, MD, FACP
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
CME/CE Virtual Event
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
July 08, 2026
06:00 PM - 07:30 PM ET
1.50 credits
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
MinuteCE®
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Adam J. Luginbuhl, MD
0.50 program credits
- Adam J. Luginbuhl, MD
0.50 program credits
Partnering Through Treatment: Preparing for Immunotherapy in the Perioperative Setting
Partnering Through Treatment: Preparing for Immunotherapy in the Perioperative Setting
MinuteCE®
Partnering Through Treatment: Preparing for Immunotherapy in the Perioperative Setting
Jennifer Johnson, MD, PhD
0.50 program credits
- Jennifer Johnson, MD, PhD
0.50 program credits

DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease

DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease

Recommended

Title